
Scott Kopetz: A Promising Strategy for KRASi Resistance
Scott Kopetz, Associate Vice President for Translational Integration at MD Anderson Cancer Center, shared a post on X about recent paper by Madelaine S. Theardy et al., published in Cell Reports Medicine.
“Targeting the YAP-SDC1 axis overcomes resistance to KRASi in GI cancers by blocking SDC1-driven macropinocytosis and RTK activation, offering a promising strategy for KRASi resistance.”
Title: Therapeutic targeting of syndecan-1 axis overcomes acquired resistance to KRAS-targeted therapy in gastrointestinal cancers
Authors: Madelaine S. Theardy, Mitsunobu Takeda, Alexey Sorokin, Shuaitong Chen, Zecheng Yang, Xiaofei Wang, Preeti Kanikarla, Oluwadara Coker, Phuoc Nguyen, Yongkun Wei, Jun Yao, Liang Yan, Yanqing Jin, Yiming Cai, Masakatsu Paku, Ziheng Chen, Kara Z. Li, Francesca Citron, Hideo Tomihara, Sisi Gao, Angela K. Deem, Jun Zhao, Huamin Wang, Samir Hanash, Ronald A. DePinho, Anirban Maitra, Giulio F. Draetta, Haoqiang Ying, Scott Kopetz, Wantong Yao
Read The Full Article at Cell Reports Medicine.
More posts featuring Scott Kopetz on OncoDaily.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023